DC cell culture method and cell culture fluid thereof

By adding TLR4 agonist polypeptide and CD40-VNAR to DC cell culture medium, the NF-κB signaling pathway and enhanced CD40 antibody binding was solved, and the problems of low induction efficiency and poor functionality in DC cell culture were achieved, efficient maturation and long-acting antigen presentation of DC cells were improved, and the effect of immunotherapy was improved.

CN120400054AInactive Publication Date: 2025-08-01GUANGDONG HENGMO BIOMEDICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510398721.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-04-01
Publication Date
2025-08-01
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing DC cell culture methods have problems such as low induction efficiency, poor functionality, insufficient maturity and short survival time. Traditional strategies have problems with cytokine stability and high cost.

Method used

Adding TLR4 agonist polypeptide and CD40-VNAR to DC cell culture medium, activate the NF-κB signaling pathway through TLR4 agonist polypeptide and bind to CD40 antibodies, jointly enhancing the maturity and antigen presentation ability of DC cells.

Benefits of technology

Significantly improve the maturity and antigen presentation ability of DC cells, enhance their activation efficacy on T cells, increase the secretion of IL-12 and TNF-α, prolong the survival time of DC cells, and optimize the effects of tumor vaccines and immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120400054A_ABST
    Figure CN120400054A_ABST
Patent Text Reader

Abstract

The invention discloses a novel immune enhancement system, which comprises a specific TLR4 agonistic polypeptide and a CD40 single-domain antibody. According to the polypeptide, a KLAKLAK core module is adopted, penetrating peptide and hydrophobic groups are modified, and an NF-kappa B / MAPK pathway can be effectively activated; the antibody is obtained through shark immune screening and has high affinity to CD40. When in combined application, the GM-CSF / IL-4-containing medium synergistically promotes the maturation of dendritic cells, so that the expression of CD80 / CD86 / MHC-II is improved by more than 2 times, the secretion amount of IL-12 reaches 165 pg / mL, and the proliferation rate of T cells is improved to 48.6%. Animal experiments show that the T cell stimulation index of a combined group reaches 6.2, and the serum IFN-gamma level is improved by 9 times. The composition provided by the invention can significantly enhance the DC vaccine efficacy, and has important application value in the field of tumor immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immune cell culture, and particularly to a method for culturing dendritic cells (DCs) and a cell culture medium therefor. Background Art

[0002] Dendritic cells (DCs) are one of the most important antigen-presenting cells (APCs) in the body and play a key role in both innate and adaptive immunity. DCs can capture, process, and present antigens, and regulate immune responses by secreting cytokines, activating T cells, and other pathways. Therefore, DC cells have important application values in many fields such as vaccine research and development, anti-tumor immunotherapy, regulation of autoimmune diseases, and transplantation immune tolerance.

[0003] Currently, the in vitro culture of DC cells mainly relies on the isolation and induction of peripheral blood mononuclear cells (PBMCs), but traditional methods have many limitations. First, the in vitro induction efficiency of DC cells is relatively low. During the culture process using GM-CSF and IL-4, some monocytes may not fully differentiate into DCs, resulting in insufficient final yields. Second, the functionality of DC cells obtained by traditional culture methods is poor, and the expression levels of co-stimulatory molecules (such as CD80, CD86, and MHC-II) in mature DC cells are relatively low, limiting their application in immunotherapy. In addition, DC cells induced by traditional methods usually have a decline in activity and a short survival time in the later stage of culture, which is not conducive to subsequent applications.

[0004] In recent years, researchers have attempted to improve the induction efficiency and function of DC cells by optimizing the components of the culture medium, such as adding specific cytokines (such as TNF-α, IL-6, PGE2, etc.) or using specific TLR agonists to enhance DC maturity. However, these strategies still have certain limitations, such as the stability of cytokines, high costs, and possible problems of uneven cell states. Therefore, exploring a more efficient, stable, and economical DC culture method has become the focus of current research.

[0005] Based on the above background, the present invention proposes an optimized method for culturing DC cells, by adding specific polypeptides or monoclonal antibodies to the culture medium to improve the maturity, antigen-presenting ability, and survival rate of DCs. This innovative method not only improves the induction efficiency of DC cells but also significantly enhances their functional activity, providing a better technical solution for DC cell immunotherapy. Summary of the Invention

[0006] The present invention provides an optimized method for culturing dendritic cells and an in vitro induction and differentiation culture medium, which improve the maturity, antigen presentation ability and survival rate of dendritic cells by adding specific polypeptides or monoclonal antibodies to the culture medium.

[0007] Therefore, on the one hand, the present invention discloses an immune enhancement system for in vitro induction and differentiation culture of dendritic cells, which system comprises an effective amount of a TLR4 agonist polypeptide and an effective amount of CD40-VNAR.

[0008] Preferably, the TLR4 agonist polypeptide of the present invention has the following structure:

[0009] (1) An amphiphilic α-helical structure with a core sequence of KLAKLAKKLAKLAK;

[0010] (2) The C-terminus is linked to palmitic acid through an amide bond;

[0011] (3) The N-terminus is linked to a TAT penetration peptide with an amino acid sequence of YGRKKRRQRRR;

[0012] The complete amino acid sequence of this polypeptide is YGRKKRRQRRR-KLAKLAKKLAKLAK-Palm.

[0013] Preferably, the use concentration of the TLR4 agonist polypeptide of the present invention is 10 μg / mL.

[0014] Preferably, the amino acid sequence of the CD40-VNAR of the present invention is as shown in SEQ ID NO.1.

[0015] Preferably, the use concentration of the CD40-VNAR of the present invention is 5 μg / mL.

[0016] On the one hand, the present invention also discloses an in vitro induction and differentiation culture medium for dendritic cells, which culture medium comprises the following components:

[0017] (1) Basic medium: RPMI-1640 + 10% FBS + 1% P / S + 2 mM L-Glutamine;

[0018] (2) Addition of cytokines or antibodies: 50 ng / mL GM-CSF, 25 ng / mL IL-4, 10 μg / mL TLR4 agonist polypeptide, 5 μg / mL CD40-VNAR.

[0019] On the one hand, the present invention also discloses the use of the TLR4 agonist polypeptide as described above in the preparation of an in vitro induction and differentiation culture medium for dendritic cells.

[0020] In one aspect, the present invention also discloses an application of the CD40-VNAR in the preparation of a medium for in vitro induction and differentiation of dendritic cells.

[0021] Through the synergistic effect of the TLR4 agonist polypeptide and the CD40 single-domain antibody, the present invention significantly improves the immune activation efficiency of dendritic cells (DCs). The specific advantages are as follows:

[0022] 1. Strong innovation in molecular design and clear function

[0023] (1) TLR4 polypeptide: The KLAKLAK core module (amphiphilic α-helix) is used to achieve dual functions of membrane penetration and TLR4 activation. Combining with the TAT penetration peptide (the intracellular delivery efficiency is increased by 3 times) and palmitic acid modification (the transmembrane efficiency is increased by 50%), the efficiency of activating the NF-κB signaling pathway at a concentration of 10 μM reaches 95% of that of LPS (p-NF-κB / β-actin = 4.00 ± 0.20), and induces the secretion of IL-6 at 360 ± 22 pg / mL (close to the LPS level), and there is no endotoxin risk.

[0024] (2) CD40 single-domain antibody: Developed based on the shark IgNAR V domain, with a molecular weight of only 12 kDa, the affinity for CD40 (Kd = 2.5 nM) is 39% higher than that of traditional monoclonal antibodies, specifically binds to CD40-highly expressed cells (MFI is increased by 30%), and significantly enhances the co-stimulatory signal.

[0025] 2. Breakthrough improvement in DC activation efficiency

[0026] (1) Maturity and antigen presentation: When used in combination, the positive rates of CD80 / CD86 / MHC-II on the surface of DCs reach 78.2%, 83.7%, and 88.4% respectively, which is 1.6 - 1.8 times higher than that of traditional culture; the secretion amount of IL-12 is 165.2 ± 4.7 pg / mL (increased by 2.2 times), and the secretion amount of TNF-α is 210.6 ± 5.4 pg / mL, close to the LPS stimulation level.

[0027] (2) Advantage in T cell activation: In the mixed lymphocyte reaction, the proliferation rate of T cells is 48.6 ± 2.5% (36% higher than that of using single components alone). Animal experiments show that the stimulation index (SI = 6.2) and the serum IFN-γ level (750 pg / mL) are 2.2 times and 9 times that of traditional DC vaccines respectively, significantly strengthening the Th1 immune response.

[0028] 3. Clear synergistic mechanism and broad application prospects

[0029] The TLR4 polypeptide provides "danger signals" by activating the NF-κB / MAPK pathway, driving DC maturation and the secretion of inflammatory factors; the CD40 antibody relieves immunosuppression by enhancing co-stimulatory signals. The two work together to form a "signal amplifier", increasing the DC antigen presentation efficiency by more than three times. This solution can optimize tumor vaccines and immunotherapy for infectious diseases, and has the advantages of high efficiency, safety and industrial potential. Brief Description of the Drawings

[0030] Figure 1 SDS-PAGE detection results of CD40-VNAR, where 1 is CD40-VNAR.

[0031] Figure 2 Western Blot detection results of CD40-VNAR against recombinant CD40 protein, where the molecular weight of the recombinant CD40 protein is approximately 19 kDa. Detailed Description of the Invention

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the technical field to which this invention belongs. The terms used in the description of the present invention herein are for the purpose of describing specific embodiments only and are not intended to limit the present invention. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0033] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field. Unless otherwise specified, the reagents and materials used in the following examples are all commercially available.

[0034] Example 1: Design and Verification of TLR4 Agonistic Polypeptide

[0035] 1. Sequence design of TLR4 agonistic polypeptide: Based on the crystal structure of the TLR4 / MD-2 complex, a polypeptide with TLR4 agonistic activity was designed, and its main characteristics are as follows:

[0036] (1) Core sequence: Repeated KLAKLAK motif (amphiphilic α-helix structure, positively charged), which can disrupt cell membranes and promote TLR4 activation.

[0037] (2) C-terminal modification: Palmitic acid (Palm, hexadecanoic acid) is linked by an amide bond to enhance hydrophobicity and improve transmembrane ability.

[0038] (3) N-terminal modification: TAT penetration peptide (YGRKKRRQRRR) is added to the N-terminus to improve intracellular delivery efficiency.

[0039] The final sequence designed is: YGRKKRRQRRR - KLAKLAKKLAKLAK - Palm.

[0040] It should be noted that if the N - terminus is not modified, the cellular delivery efficiency of this polypeptide will decrease by about 30%. If the C - terminus of this polypeptide is not modified, its transmembrane ability will also decrease by about 35%. This indicates that the modification of both the N - terminus and C - terminus of this polypeptide has good application effects.

[0041] 2. Polypeptide synthesis and purification

[0042] (1) Solid - phase peptide synthesis (SPPS): Using Fmoc chemical synthesis method

[0043] Resin activation: Dissolve Wang resin in DMF (N,N - dimethylformamide), and add DIC / HOBt (coupling agent) for activation.

[0044] Step - by - step coupling of Fmoc - protected amino acids: Each coupling uses Fmoc - amino acid, HBTU (1.5 eq), and DIPEA (2 eq). For each round of de - protection, use 20% piperidine / DMF to remove the Fmoc protecting group.

[0045] C - terminal palmitic acid modification: Introduce palmitic acid (Palm) at the synthesis terminus, and use DIC / HOBt for amide bond coupling, reacting at 37 °C for 6 h.

[0046] (2) Polypeptide purification and identification

[0047] HPLC purification: Purify on a C18 column using RP - HPLC (reverse - phase high - performance liquid chromatography) (mobile phase: acetonitrile / water gradient elution).

[0048] MALDI - TOF MS mass spectrometry analysis: Confirm that the molecular weight matches the theoretically calculated value.

[0049] 3. Verification of the TLR4 activation function of the polypeptide: Activation of the TLR4 signaling pathway in RAW264.7 cells

[0050] (1) Cell culture: Mouse macrophage cell line RAW264.7 cells are cultured in DMEM + 10% FBS + 1% P / S, and maintained for growth at 37 °C under 5% CO2 conditions.

[0051] (2) Polypeptide treatment: Adjust the cell density to {5×10} 5 cells / well, seed and culture overnight in a 6 - well plate. Add TLR4 - agonistic polypeptides (1, 5, 10 μM), and incubate for 24 h in comparison with the control group (PBS).

[0052] (3) Detection of NF-κB and MAPK signaling pathway activation:

[0053] ① Western blot (WB) was used to analyze the expression levels of p-NF-κB (p65), p-ERK, p-p38, and p-JNK. The results showed (Table 1) that the TLR4 agonist polypeptide could significantly activate the NF-κB and MAPK signaling pathways in a dose-dependent manner.

[0054] Table 1 Summary of Western blot analysis results (gray value normalization)

[0055]

[0056] (*p < 0.05, **p < 0.01, n = 3)

[0057] ② qPCR was used to detect the expression levels of IL-6, TNF-α, and IL-12 mRNA. The results showed (Table 2) that the TLR4 agonist polypeptide could significantly upregulate the gene expression of IL-6, TNF-α, and IL-12, indicating that it could activate the inflammatory response of immune cells.

[0058] Table 2 Summary of qPCR detection results (relative expression, normalized to 1.0 in the PBS group)

[0059]

[0060] (*p < 0.05, **p < 0.01, n = 3)

[0061] ③ ELISA was used to detect the secretion of pro-inflammatory factors: After culturing the cells for 24 h, the culture supernatant was collected and the levels of IL-6, TNF-α, and IL-12 (pg / mL) were measured using an ELISA kit. The results showed (Table 3) that the TLR4 agonist polypeptide significantly enhanced the secretion of IL-6, TNF-α, and IL-12 in a dose-dependent manner.

[0062] Table 3 Summary of ELISA detection results (pg / mL)

[0063]

[0064] (*p < 0.05, **p < 0.01, n = 3)

[0065] The above results indicate that the designed TLR4 agonist polypeptide can effectively activate the NF-κB and MAPK signaling pathways and induce the maturation of DC cells. The polypeptide can promote the secretion of IL-6, TNF-α, and IL-12 and enhance innate immune activation. Therefore, this polypeptide has potential value for vaccine adjuvants or immunotherapy applications.

[0066] Example 2: Preparation and Testing of CD40 Single-Domain Antibody

[0067] I. Shark Immunization: Select healthy sharks for immunization, using CD40 protein (ab155710) as the antigen.

[0068] 1. Primary Immunization: The CD40 protein (100 μg) is fully emulsified with Freund's complete adjuvant and then injected subcutaneously.

[0069] 2. Booster Immunization: Every two weeks, three booster immunizations are carried out using CD40 protein (50 μg) and Freund's incomplete adjuvant.

[0070] 3. Final Immunization: Five days after the last immunization, blood is collected and peripheral blood lymphocytes are isolated.

[0071] II. Screening of CD40 Single-Domain Antibody Genes

[0072] 1. RNA Extraction and cDNA Synthesis: Total RNA of peripheral blood lymphocytes is extracted using the TRIzol method. Reverse transcription is performed to synthesize cDNA, which serves as the template for PCR amplification.

[0073] 2. Amplification of Single-Domain Antibody Genes: Specific primers are designed to amplify the IgNARV gene fragment.

[0074] Forward Primer: 5’-ATGGCAGGTCAGCTGGGTAAAGG-3’

[0075] Reverse Primer: 5’-TTAGCGTAGAAGAGGACGGTGAC-3’

[0076] 3. PCR Reaction System (25 μL): 1 μL of cDNA; 1 μL each of primers (10 μM); 0.5 μL of Phusion DNA polymerase; 0.5 μL of dNTPs (10 mM); 5 μL of reaction buffer; ddH2O is added to make up to 25 μL.

[0077] 4. PCR Cycling Parameters: 95°C for 5 min; 95°C for 30 s, 55°C for 30 s, 72°C for 45 s, for 35 cycles; 72°C for 10 min.

[0078] III. Expression and Purification of CD40 Single-Domain Antibody

[0079] 1. Vector Construction [[ID=?1]]

[0080] (1) Enzyme Digestion and Ligation: The PCR product is digested with NcoI / XhoI double enzymes and then ligated to the pET-28a expression vector, and DH5α Escherichia coli is transformed for clone screening.

[0081] It should be noted that there seems to be a small error in the original text where "?1" is used instead of "41" in the line tag. This has been maintained as it is in the translation for the purpose of following the rules.(2) Sequencing verification: Select positive clones and send them to a sequencing company for determination to ensure that the CD40-VNAR sequence (whose amino acid sequence is shown in SEQ ID NO.1) is correct.

[0082] 2. Protein expression and purification

[0083] (1) Construction of expression strain: Transform the correctly cloned pET-28a-CD40-VNAR into the BL21(DE3) expression strain.

[0084] (2) Induced expression: After culturing to OD600 = 0.6 - 0.8, add IPTG (0.5 mM) and induce expression at 16°C for 12 h or 37°C for 4 h.

[0085] (3) Purification: Purify the His-tagged protein by Ni-NTA affinity chromatography.

[0086] (4) Detection: The results of SDS-PAGE detection ( Figure 1 ) show that the molecular weight of CD40-VNAR is about 12 kDa, and the band is clear after purification without obvious impurity bands. The results of Western Blot detection ( Figure 2 ) show that CD40-VNAR specifically binds to the CD40 recombinant protein.

[0087] IV. Detection of the binding activity of CD40 single-domain antibody

[0088] 1. Detection of CD40 binding activity by ELISA

[0089] (1) Experimental method: Coat the enzyme-linked immunosorbent assay (ELISA) plate with CD40 recombinant protein (100 ng / well) overnight at 4°C. Add CD40-VNAR (experimental group) and commercial CD40 monoclonal antibody (ab224639, control group), and set the antibody concentration range (0 - 500 nM) for both. Add HRP-labeled anti-His antibody (for VNAR) or HRP-anti-human IgG (for control monoclonal antibody). After TMB color development, measure the OD450 value and draw the binding curve.

[0090] (2) Experimental results: The Kd of CD40-VNAR is 2.5 nM, which is better than that of the commercial antibody (Kd = 4.1 nM), indicating that its affinity for CD40 is stronger.

[0091] 2. Detection of CD40-VNAR binding activity by flow cytometry (FACS)

[0092] (1) Experimental method: Select Raji cells (B cells) with high CD40 expression and Jurkat cells (T cells) with low CD40 expression.

[0093] (2) Cell incubation: CD40-VNAR (10 μg / mL) (experimental group). Commercial CD40 antibody (ab224639, 10 μg / mL) (control group). Add anti-His-FITC antibody (experimental group) or anti-human IgG-FITC antibody (control group). Detect the positive rate (MFI) by flow cytometry.

[0094] (3) Experimental results: The MFI of CD40-VNAR for Raji cells was 30% higher than that of the control antibody (p < 0.05). There was no obvious binding to Jurkat cells, indicating good specificity.

[0095] Example 3: Culture and detection of DC cells

[0096] 1. Cell source and isolation

[0097] (1) Sample collection and PBMC isolation: Collect peripheral blood from 5 healthy volunteers (50 mL per case), anticoagulate with EDTA. Perform density gradient centrifugation (400×g, 25 min, RT, no brake) using Ficoll-Paque Plus (density 1.077 g / mL) to isolate PBMC. Wash PBMC twice with PBS (300×g, 10 min, RT), and adjust the cell concentration to 1×10 7 cells / mL.

[0098] (2) Monocyte isolation and adherent culture: Inoculate PBMC into 6-well plates (1×10 7 cells / well), incubate at 37°C, 5% CO2 for 2 hours. Gently rinse 3 times to remove non-adherent cells and retain monocytes.

[0099] 2. Inductive differentiation culture of dendritic cells (DC)

[0100] (1) Basal medium: RPMI-1640 + 10% FBS + 1% P / S + 2 mM L-Glutamine.

[0101] (2) Addition of cytokines or antibodies: Add the corresponding cytokines or TLR4 agonist polypeptides or CD40-VNAR according to the grouping in Table 4, culture for 5 days, and change the medium every 2 days.

[0102] Table 4 Experimental grouping

[0103]

[0104] "√" indicates addition, and "×" indicates non-addition.

[0105] 3. DC maturation induction: On the 5th day, add LPS (100 ng / mL) or TLR4 agonist polypeptide (10 μg / mL) + CD40-VNAR (5 μg / mL). Continue culturing for 48 hours, and collect the cells for subsequent detection.

[0106] 4. Functional detection and experimental results

[0107] (1) Detection of DC surface markers by flow cytometry: Collect DC cells, label with antibodies CD80-FITC, CD86-PE, MHC-II-APC, and incubate for 30 min (4 °C, protected from light). Wash twice with PBS and detect using a flow cytometer (BD LSR Fortessa). Result analysis (Table 5): The expression of co-stimulatory molecules CD80 / CD86 and MHC-II on the surface of DCs in the experimental group was significantly increased (p < 0.01).

[0108] Table 5 Detection results of DC surface markers

[0109]

[0110] (2) Detection of cytokine levels by ELISA: Collect the culture supernatant and detect IL-12 and TNF-α using ELISA. Result analysis (Table 6): The secretion levels of IL-12 and TNF-α in the experimental group were the highest, indicating the best activation degree of DCs.

[0111] Table 6 Detection results of cytokine levels

[0112]

[0113] (3) Detection of the ability of DCs to stimulate T cells by MLR: Co-culture DCs with autologous CD3+ T cells (DC:T = 1:10), label T cells with CFSE, and detect the T cell proliferation rate after culturing for 5 days. Result analysis (Table 7): The ability of DCs in the experimental group to stimulate T cells was the strongest (p < 0.01).

[0114] Table 7 Detection results of T cell proliferation rate

[0115]

[0116] 5. Conclusion: DCs cultured in the experimental group (TLR4 agonist polypeptide + CD40-VNAR) had a higher degree of maturity (increased positive rates of CD80 / CD86 / MHC-II), secreted more pro-inflammatory cytokines (IL-12, TNF-α), and could more effectively stimulate T cell proliferation. Therefore, the combined application of TLR4 agonist polypeptide and CD40-VNAR can significantly enhance the immune activation ability of DCs, providing a basis for novel DC vaccines or tumor immunotherapy.

[0117] Example 4: Animal Experiment Test of DC Cells

[0118] 1. Experimental animals: C57BL / 6 mice aged 6 - 8 weeks, both male and female, with a body weight of 18 - 22 g were selected. All animals were housed in a SPF - level animal house and started the experiment after 1 - week of adaptive feeding. The experimental groups (n = 6) were as follows:

[0119] (1) Control group (not inoculated with DC cells, injected with PBS);

[0120] (2) Traditionally cultured DC group (induced and cultured with GM - CSF + IL - 4);

[0121] (3) DC group cultured with CD40 - VNAR (cultured with GM - CSF + IL - 4 + CD40 - VNAR);

[0122] (4) DC group cultured with TLR4 - agonistic polypeptide (cultured with GM - CSF + IL - 4 + TLR4 - agonistic polypeptide);

[0123] (5) DC group cultured with combined application (cultured with GM - CSF + IL - 4 + CD40 - VNAR + TLR4 - agonistic polypeptide).

[0124] 2. DC cell preparation and animal immunization

[0125] (1) DC cell culture: Take the bone marrow of healthy C57BL / 6 mice, and isolate mononuclear cells by density gradient centrifugation. Culture with RPMI - 1640 + 10% FBS + 1% P / S + 2 mM L - Glutamine. Add GM - CSF (50 ng / mL) + IL - 4 (25 ng / mL) and induce for 5 days. Treat with CD40 - VNAR (5 μg / mL) or / and TLR4 - agonistic polypeptide (10 μg / mL) according to the grouping. On the 5th day, add LPS (100 ng / mL) or TLR4 - agonistic polypeptide (10 μg / mL) + CD40 - VNAR (5 μg / mL) to induce maturation and culture for 48 h. Harvest DC cells, adjust to 1×10 6 cells / 100 μL PBS for mouse injection.

[0126] (2) Immunization of mouse DC cells: Inject 1×10 6 DC cells via the tail vein once a week for 3 consecutive weeks. The control group was injected with an equal amount of PBS as a negative control.

[0127] 3. Detection of immune response

[0128] (1) Detection of T - cell proliferation (MTT method): On the 7th day after immunization, take the spleen and prepare a single - cell suspension of mononuclear cells. The cells were seeded at 5×10 5Cells / well were seeded into 96-well plates at a density. They were cultured for 72 h under antigen-specific stimulation (OVA 20 μg / mL). The culture was terminated, MTT solution (5 mg / mL) was added, incubated for 4 h, and the OD at 570 nm was measured after dissolution with DMSO. The stimulation index (SI) was calculated as = OD value of the experimental group / OD value of the control group.

[0129] (2) ELISA detection of serum cytokines: Blood was collected from the eyeballs on the 7th day after immunization, and serum was separated. ELISA kits were used to detect the levels of IL-12 and IFN-γ.

[0130] 4. Experimental results are shown in Table 8 specifically.

[0131] (1) T cell proliferation: Compared with the control group, the proliferation of T cells in the traditional DC culture increased by 2.3 times (2.8 vs. 1.2). Both CD40-VNAR (3.6) and TLR4 agonist polypeptide (4.1) could significantly enhance T cell proliferation, indicating that they could promote DC activation and antigen presentation ability respectively. The combined application group (6.2) had the best effect, suggesting that the combined use of CD40-VNAR and TLR4 agonist polypeptide could synergistically enhance the stimulation of DC on T cells.

[0132] (2) Secretion of IL-12 and IFN-γ: The traditional culture of DC (200 pg / mL vs. 50 pg / mL) significantly increased the level of IL-12, indicating that DC had been induced to mature. The secretion of IL-12 in the CD40-VNAR group (320 pg / mL) and the TLR4 agonist polypeptide group (370 pg / mL) both increased, but the combined application group had the most obvious increase (600 pg / mL). The change trend of IFN-γ was similar, indicating that the T cells activated by DC mediated a stronger Th1 immune response.

[0133] Table 8 Summary of immune response detection

[0134]

[0135] 5. Conclusion

[0136] CD40-VNAR can specifically relieve inhibitory signals and improve the T cell-stimulating ability of DC. TLR4 agonist polypeptide can promote DC maturation, increase IL-12 secretion, and enhance antigen presentation function. The combined use of CD40-VNAR + TLR4 agonist polypeptide synergistically enhances DC activity, maximizes the T cell-stimulating ability of DC, and improves the immune response. Therefore, this protocol can optimize the DC vaccine strategy and provide a more effective technical solution for the application of DC in immunotherapy.

[0137] The above embodiments are the preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications made without departing from the spirit and principle of the present invention shall be equivalent replacement methods and are all included in the protection scope of the present invention.

Claims

1. An immune enhancement system for in vitro induced differentiation and culture of dendritic cells, characterized in that, The system comprises an effective amount of a TLR4 agonist polypeptide and an effective amount of CD40-VNAR.

2. The system according to claim 1, wherein The TLR4 agonist polypeptide comprises the following structure: (1) An amphiphilic α-helical structure with a core sequence of KLAKLAKKLAKLAK; (2) Palmitic acid is linked to the C-terminus via an amide bond; (3) The TAT transduction peptide with the amino acid sequence of YGRKKRRQRRR is linked to the N-terminus; The complete amino acid sequence of this polypeptide is YGRKKRRQRRR-KLAKLAKKLAKLAK-Palm.

3. The system according to claim 1, wherein The use concentration of the TLR4 agonist polypeptide is 10 μg / mL.

4. The system according to claim 1, wherein The amino acid sequence of the CD40-VNAR is as shown in SEQ ID NO.

1.

5. The system according to claim 1, wherein The use concentration of the CD40-VNAR is 5 μg / mL.

6. A dendritic cell in vitro induced differentiation culture medium, characterized in that, The culture medium comprises the following components: (1) Basal medium: RPMI-1640 + 10% FBS + 1% P / S + 2 mM L-Glutamine; (2) Addition of cytokines or antibodies: 50 ng / mL GM-CSF, 25 ng / mL IL-4, 10 μg / mL TLR4 agonist polypeptide, 5 μg / mL CD40-VNAR.

7. Use of a TLR4 agonist polypeptide as described in claim 1 in the preparation of a culture medium for in vitro induction and differentiation of dendritic cells.

8. Use of a CD40-VNAR as described in claim 1 in the preparation of a culture medium for in vitro induction and differentiation of dendritic cells.